



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIBDATASHEET

CONFIRMATION NO. 2000

Bib Data Sheet

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| SERIAL NUMBER 10/521,508 | FILING OR 371(c) DATE 01/18/2005 RULE | CLASS 514 | GROUP ART UNIT 1614 | ATTORNEY DOCKET NO. MC060P |
| APPLICANTS Yongxin Han, Kirkland, CANADA; John Colucci, Westmount, CANADA; Xavier Billot, Montreal, CANADA; Marie-Claire Wilson, Montreal, CANADA; Robert Young, Senneville, CANADA; | | | | |
| ** CONTINUING DATA ***** This application is a 371 of PCT/CA03/01306 08/25/2003 which claims benefit of 60/406,530 08/28/2002 | | | | |
| ** FOREIGN APPLICATIONS ***** | | | | |
| Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met Allowance Verified and Acknowledged <u>Examiner's Signature</u> <u>Initials</u> | | STATE OR COUNTRY CANADA | SHEETS DRAWING | TOTAL CLAIMS 15 |
| | | | | INDEPENDENT CLAIMS 2 |
| ADDRESS 000210 | | | | |
| TITLE Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma | | | | |
| FILING FEE RECEIVED 900 | FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following: | | <input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit | |